JMP Securities set a $21.00 price objective on Intra-Cellular Therapies (NASDAQ:ITCI) in a research report report published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the company. Jefferies Financial Group began coverage on Intra-Cellular Therapies in a report on Monday, August 12th. They issued a buy rating and a $16.00 target price on the stock. BidaskClub upgraded shares of Intra-Cellular Therapies from a strong sell rating to a sell rating in a report on Saturday. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a buy rating to a hold rating in a research report on Thursday, July 18th. ValuEngine lowered shares of Intra-Cellular Therapies from a buy rating to a hold rating in a research note on Wednesday, September 4th. Finally, Cowen restated a buy rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a report on Monday, July 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. Intra-Cellular Therapies currently has a consensus rating of Buy and a consensus price target of $23.63.
Shares of ITCI stock traded down $0.21 on Tuesday, reaching $10.19. 827,927 shares of the company’s stock traded hands, compared to its average volume of 657,422. Intra-Cellular Therapies has a 12-month low of $7.41 and a 12-month high of $23.62. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.86 and a current ratio of 8.86. The company has a market capitalization of $564.67 million, a P/E ratio of -3.59 and a beta of 1.19. The business’s 50 day moving average price is $8.84 and its two-hundred day moving average price is $11.76.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.15. Research analysts predict that Intra-Cellular Therapies will post -3.39 earnings per share for the current year.
In other Intra-Cellular Therapies news, Director Christopher D. Alafi acquired 125,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 30th. The stock was acquired at an average price of $8.52 per share, with a total value of $1,065,000.00. Following the purchase, the director now owns 341,223 shares in the company, valued at $2,907,219.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher D. Alafi acquired 485,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average cost of $10.26 per share, with a total value of $4,976,100.00. Following the purchase, the director now owns 341,223 shares in the company, valued at approximately $3,500,947.98. The disclosure for this purchase can be found here. 18.20% of the stock is owned by insiders.
Large investors have recently modified their holdings of the stock. Quantamental Technologies LLC acquired a new position in Intra-Cellular Therapies during the second quarter worth $49,000. Bank of Montreal Can raised its holdings in Intra-Cellular Therapies by 114.4% during the second quarter. Bank of Montreal Can now owns 7,067 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 3,771 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Intra-Cellular Therapies by 883.0% in the first quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 9,307 shares during the last quarter. First Mercantile Trust Co. lifted its position in shares of Intra-Cellular Therapies by 12.3% in the first quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 1,265 shares during the last quarter. Finally, Slow Capital Inc. acquired a new stake in shares of Intra-Cellular Therapies in the second quarter worth about $195,000. Hedge funds and other institutional investors own 68.97% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Further Reading: What is quantitative easing?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.